The Chugai partnership and cash runway into Q4 2027 de-risk near-term funding needs. Traders should monitor upcoming Phase 1 data readouts for RT-114 as the next major catalyst, which could validate the RaniPill® platform and trigger further partnership or licensing activity.
Price Chart
Executive Summary
Rani Therapeutics reported its 2025 financial results alongside major corporate developments, including a $1.085 billion collaboration with Chugai Pharmaceutical, completion of a $60.3 million private placement, and initiation of a Phase 1 trial for its oral GLP-1/GLP-2 dual agonist RT-114. Despite minimal revenue, the company significantly strengthened its balance sheet and eliminated all debt, positioning itself for clinical advancement of its RaniPill® platform in obesity and rare diseases.
Key Financial Metrics
Key Facts
- Entered $1.085 billion potential collaboration with Chugai for oral delivery of a rare disease antibody using RaniPill®
- Raised $60.3 million in oversubscribed private placement, including $6.0 million debt conversion
- Initiated Phase 1 trial for RT-114 (oral GLP-1/GLP-2 dual agonist) in obesity in December 2025
- Preclinical data show bioequivalence of oral semaglutide and RT-114 to subcutaneous delivery
- Cash, cash equivalents, and marketable securities increased to $49.7 million from $27.6 million in 2024
- Eliminated all debt obligations, including $6.2 million principal repayment to Avenue
- Contract revenue was $1.6 million in 2025 vs. $1.0 million in 2024, primarily from Chugai upfront payment being recognized over time
- Net loss narrowed to $41.0 million in 2025 from $56.6 million in 2024 due to cost containment
Financial Impact
Cash position increased by 80% YoY to $49.7M; R&D and G&A expenses reduced by $10.7M combined; net loss improved by $15.6M despite minimal revenue
Risk Factors
- Revenue remains minimal ($1.6M) and dependent on future milestone payments from Chugai
- Clinical development risk: Phase 1 data for RT-114 may not replicate preclinical bioequivalence in humans
- High share count dilution: Class A shares outstanding increased from 33.4M to 97.6M in 2025
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263414 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 11w ago | 8-K | $0.8200 $0.8645 | ▲ +5.43% | ▲ +6.66% | $0.6170 (−24.76%) |
Jul 15, 2026 14w ago | Press Release | $0.6770 $0.8028 | ▲ +18.58% | ▲ +16.24% | $0.6170 (−8.86%) |
May 15, 2026 23w ago | Press Release | $0.9720 $0.7597 | ▼ −21.84% | ▼ −23.42% | $0.6170 (−36.52%) |
Mar 26, 2026 30w ago | Press Release | $0.8110 $0.8900 | ▲ +9.74% | ▼ −3.00% | $0.6170 (−23.92%) |
Mar 19, 2026 31w ago | Press Release | $1.13 $0.9740 | ▼ −13.81% | ▼ −23.12% | $0.6170 (−45.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers